Faes Farma SA (ES:FAE)
BME:FAE
Want to see ES:FAE full AI Analyst Report?
FAE Stock Chart & Stats
€5.22
€0.00(0.00%)
At close: 4:00 PM EST
€5.22
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.10 - €5.44
Previous CloseN/A
Volume18.30K
Average Volume (3M)130.56K
Market Cap
€1.45B
Enterprise Value€1.74B
Total Cash (Recent Filing)€130.09M
Total Debt (Recent Filing)€409.91M
Price to Earnings (P/E)10.7
Beta0.44
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)0.26
Shares Outstanding316,223,940
10 Day Avg. Volume112,243
30 Day Avg. Volume130,562
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)2.16
Price to Sales (P/S)2.63
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)€731.75M
Bulls Say, Bears Say
Bulls Say
Historical ProfitabilitySustained high gross and net margins from 2020–2024 indicate durable earnings power and operating leverage in the core business. This historical profitability supports ongoing R&D, manufacturing investment and provides a buffer to absorb near-term shocks while pursuing long-term product development.
Conservative Equity BaseA historically conservative balance sheet and a sizable equity base provide financial resilience: they lower refinancing risk, support funding for clinical programs or acquisitions, and allow flexibility in capital allocation even after the recent rise in leverage.
Consistent Cash GenerationRegular positive operating and free cash flow in most years indicates ability to self-fund operations, capex and dividend payments. Over a multi-quarter horizon this supports steady investment in manufacturing and commercialization without relying solely on external financing.
Bears Say
2025 Revenue And Margin DeteriorationA meaningful revenue decline and sharp margin compression in 2025 signal structural pressure on sales mix, pricing or product competitiveness. If persistent, this erodes reinvestment capacity for R&D and commercialization and heightens execution risk over the next several quarters.
Rising Leverage In 2025A material jump in leverage reduces balance sheet flexibility and raises interest and covenant risk. This constrains options for opportunistic M&A, larger R&D programs or aggressive commercial expansion and increases vulnerability if cash generation weakens further.
Weaker Cash Conversion In Recent YearDeclining cash conversion and a 20.6% drop in free cash flow reduce internal funding for clinical and commercial initiatives and make deleveraging slower. Over a multi-quarter horizon, this raises financing needs or forces trade-offs in capex, dividends or R&D spend.
Faes Farma News
FAE FAQ
What was Faes Farma SA’s price range in the past 12 months?
Faes Farma SA lowest stock price was €4.10 and its highest was €5.44 in the past 12 months.
What is Faes Farma SA’s market cap?
Faes Farma SA’s market cap is €1.45B.
When is Faes Farma SA’s upcoming earnings report date?
Faes Farma SA’s upcoming earnings report date is Aug 04, 2026 which is in 63 days.
How were Faes Farma SA’s earnings last quarter?
Currently, no data Available
Is Faes Farma SA overvalued?
According to Wall Street analysts Faes Farma SA’s price is currently Overvalued.
Does Faes Farma SA pay dividends?
Faes Farma SA pays a Semiannually dividend of €0.033 which represents an annual dividend yield of 3.51%. See more information on Faes Farma SA dividends here
What is Faes Farma SA’s EPS estimate?
Faes Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Faes Farma SA have?
Faes Farma SA has 316,223,940 shares outstanding.
What happened to Faes Farma SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Faes Farma SA?
Currently, no hedge funds are holding shares in ES:FAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faes Farma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.24%
12-Months-Change
Fundamentals
Return on Equity
18.13%
Trailing 12-Months
Asset Growth
57.30%
Trailing 12-Months
Company Description
Faes Farma SA
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
Technical Analysis
Almirall
―
Grifols
―
LABORATORIO REIG JOFRE
―
Compania de Distribucion Integral Logista Holdings
―
Naturhouse Health
―
Options Prices
Currently, No data available
---